Publication Name	World Journal of Orthopedics
Manuscript ID	94859
Country	China

Received	2024-03-27 01:54
Peer-Review Started	2024-03-27 01:54
To Make the First Decision
Return for Revision	2024-07-25 05:28
Revised	2024-07-27 10:00
Second Decision	2024-08-19 02:37
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-08-19 07:00
Articles in Press	2024-08-19 07:00
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2024-08-23 06:53
Publish the Manuscript Online	2024-09-12 12:30

ISSN	2218-5836 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Pharmacology & Pharmacy
Manuscript Type	Editorial
Article Title	Evolution of treatment options for juvenile idiopathic arthritis
Manuscript Source	Invited Manuscript
All Author List	Tao Ren, Jia-Hui Guan, Yu Li, Nan-Nan Li and Zheng Li
ORCID	Author(s) ORCID Number Nan-Nan Li http://orcid.org/0009-0007-8740-5201 Zheng Li http://orcid.org/0000-0002-2882-6600
Funding Agency and Grant Number
Corresponding Author	Zheng Li, PhD, Pharmacist, Jiangsu Engineering Research Center of Cardiovascular Drugs Targeting Endothelial Cells, College of Health Sciences, School of Life Sciences, Jiangsu Normal University, No. 101 Shanghai Road, Xuzhou 221000, Jiangsu Province, China. lizhengcpu@163.com
Key Words	Juvenile idiopathic arthritis; Treatment; Non-steroidal anti-inflammatory drug; Disease-modifying antirheumatic drug; Evolution
Core Tip	In past decades, the pharmacological treatments for juvenile idiopathic arthritis (JIA) have undergone a dramatic evolution from non-steroidal anti-inflammatory drugs to disease-modifying antirheumatic drugs (DMARDs), especially the emergence of biologic DMARDs enable patients with refractory JIA to achieve disease remission. This editorial focuses on the progress in treatment options for JIA. We hope that this editorial could provide valuable information for use of anti-JIA drugs.
Publish Date	2024-09-12 12:30
Citation	<p>Ren T, Guan JH, Li Y, Li NN, Li Z. Evolution of treatment options for juvenile idiopathic arthritis. <i>World J Orthop</i> 2024; 15(9): 831-835</p>
URL	https://www.wjgnet.com/2218-5836/full/v15/i9/831.htm
DOI	https://dx.doi.org/10.5312/wjo.v15.i9.831

Full Article (PDF)	WJO-15-831-with-cover.pdf
Manuscript File	94859_Auto_Edited_074156.docx
Answering Reviewers	94859-answering-reviewers.pdf
Audio Core Tip	94859-audio.m4a
Conflict-of-Interest Disclosure Form	94859-conflict-of-interest-statement.pdf
Copyright License Agreement	94859-copyright-assignment.pdf
Non-Native Speakers of English Editing Certificate	94859-non-native-speakers.pdf
Peer-review Report	94859-peer-reviews.pdf
Scientific Misconduct Check	94859-scientific-misconduct-check.png
Scientific Editor Work List	94859-scientific-editor-work-list.pdf
CrossCheck Report	94859-crosscheck-report.pdf